CAR-T cell potency: from structural elements to vector backbone components

Chimeric antigen receptor (CAR) T cell therapy, in which a patient’s own T lymphocytes are engineered to recognize and kill cancer cells, has achieved remarkable success in some hematological malignancies in preclinical and clinical trials, resulting in six FDA-approved CAR-T products currently avai...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazinani, Marzieh, Rahbarizadeh, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487061/
https://www.ncbi.nlm.nih.gov/pubmed/36123710
http://dx.doi.org/10.1186/s40364-022-00417-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487061/
https://www.ncbi.nlm.nih.gov/pubmed/36123710
http://dx.doi.org/10.1186/s40364-022-00417-w

Ejemplares similares